The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Survival Analysis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Survival Analysis


Psychiatry related information on Survival Analysis


High impact information on Survival Analysis

  • We applied a survival analysis adjusted for the quality of life to data from a randomized trial conducted by the AIDS Clinical Trials Group. The trial compared treatment with 500 mg of zidovudine per day, 1500 mg of zidovudine per day, and placebo (Protocol 019) in 1338 asymptomatic HIV-infected patients [9].
  • Using a combination of high-resolution magnetic resonance imaging and histopathological and survival analyses, we show that tumor progression was significantly impaired in Egr1-/- mice [10].
  • In survival analysis, time to biochemical progression (P<.001), Gleason score (P<.001), and PSA doubling time (P<.001) were predictive of the probability and time to the development of metastatic disease [11].
  • MAIN OUTCOME MEASURE: Cumulative incidence of PUBs for rofecoxib vs NSAIDs, based on survival analysis of time to first PUB diagnosis, using PUBs that met pre-specified criteria judged by a blinded, external adjudication committee [12].
  • MAIN OUTCOME MEASURES--Relative risks (RRs), estimated with Cox proportional hazards (survival) analysis, for 25-year CHD mortality for cholesterol quartiles and per 0.50-mmol/L (20-mg/dL) cholesterol increase [13].

Chemical compound and disease context of Survival Analysis


Biological context of Survival Analysis


Anatomical context of Survival Analysis

  • The present report of 1484 patients with LMCD in the Coronary Artery Surgery Study (CASS) Registry extends the originally published 5-year surgical and medical group survival analysis to more than 16 years of follow-up and permits analysis of LMCD patient subgroups [24].
  • PEA3 mRNA expression in stromal cells emerged as an independent predictor of poor outcome in multivariate survival analysis, in which all molecules previously studied in this patient cohort were included (P = 0.015) [25].
  • Multivariate survival analysis showed that both TPO.Ab and thyroid volume were independently associated with prognosis in breast carcinoma and that RRs for disease-free survival were of a similar order of magnitude to well-established prognostic indices such as axillary nodal status or tumor size [26].
  • Kaplan-Meier survival analyses showed that a slower progression of disease, i.e. higher proportion of subjects with CD4+ T cell counts > 500/microl (p = 0.0006) and a trend toward a slower progression to AIDS (p = 0.077), was associated with the CCR5/delta ccr5 genotype [27].
  • Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. Results of a multivariate survival analysis [28].

Associations of Survival Analysis with chemical compounds

  • Survival analysis with log-normal regression showed that the duration of intubation was shorter with steroid therapy (p less than 0.003) and increasing age (p less than 0.02), but was not influenced by endotracheal tube size or abnormality on chest radiograph [29].
  • Survival analysis disclosed essentially three categories of treatment response: one for noncompliant subjects (0% to 7% abstinent), one for compliant subjects not attaining therapeutic serum lithium levels (31% to 44% abstinent), and one for compliant subjects with therapeutic serum levels (67% abstinent) [30].
  • RESULTS: In an intention-to-treat survival analysis, the likelihood of treatment failure was significantly lower in the cyclophosphamide (P = 0.04) and combination therapy (P = 0.002) groups than in the methylprednisolone group [31].
  • Survival analysis demonstrated a highly significant prophylactic effect for active imipramine hydrochloride maintained at an average dose of 200 mg and a modest prophylactic effect for monthly interpersonal psychotherapy [32].
  • Using survival analysis during the entire 2 years, we did not find a significant difference between fluphenazine and placebo in the likelihood that a prodrome would continue to an exacerbation [33].

Gene context of Survival Analysis

  • Besides the traditional clinical prognostic variables, E-cad and alpha-, beta-, and gamma-catenin expression were of positive prognostic value in univariate survival analyses [34].
  • Importantly, Kaplan-Meier survival analysis and log-rank test revealed a significant inverse correlation between high nuclear EGFR and overall survival (P = 0.009) [35].
  • Survival analysis revealed a significant association of stromal SPARC with poor prognosis (P = 0.006), a finding that was also confirmed in multivariate models [36].
  • Overall survival analysis of breast carcinoma patients indicated a statistically significant correlation between SEL1L down-modulation and poor prognosis [37].
  • In Kaplan-Meyer survival analysis, there was a tendency toward a more favorable prognosis in patients with CYP2A6-positive tumors in comparison with patients with CYP2A6-negative tumors [38].

Analytical, diagnostic and therapeutic context of Survival Analysis


  1. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. Rosman, N.P., Colton, T., Labazzo, J., Gilbert, P.L., Gardella, N.B., Kaye, E.M., Van Bennekom, C., Winter, M.R. N. Engl. J. Med. (1993) [Pubmed]
  2. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Smith, J.S., Tachibana, I., Passe, S.M., Huntley, B.K., Borell, T.J., Iturria, N., O'Fallon, J.R., Schaefer, P.L., Scheithauer, B.W., James, C.D., Buckner, J.C., Jenkins, R.B. J. Natl. Cancer Inst. (2001) [Pubmed]
  3. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. Tannapfel, A., Wasner, M., Krause, K., Geissler, F., Katalinic, A., Hauss, J., Mössner, J., Engeland, K., Wittekind, C. J. Natl. Cancer Inst. (1999) [Pubmed]
  4. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Shin, H.D., Park, B.L., Kim, L.H., Jung, J.H., Kim, J.Y., Yoon, J.H., Kim, Y.J., Lee, H.S. Hum. Mol. Genet. (2003) [Pubmed]
  5. Neopterin and prognosis in patients with adenocarcinoma of the colon. Weiss, G., Kronberger, P., Conrad, F., Bodner, E., Wachter, H., Reibnegger, G. Cancer Res. (1993) [Pubmed]
  6. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. Montgomery, S.A., Mahé, V., Haudiquet, V., Hackett, D. Journal of clinical psychopharmacology. (2002) [Pubmed]
  7. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. McDermott, B.E., Sautter, F.J., Garver, D.L. Psychiatry research. (1991) [Pubmed]
  8. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease. Smith, F., Talwalker, S., Gracon, S., Srirama, M. Journal of biopharmaceutical statistics. (1996) [Pubmed]
  9. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. Lenderking, W.R., Gelber, R.D., Cotton, D.J., Cole, B.F., Goldhirsch, A., Volberding, P.A., Testa, M.A. N. Engl. J. Med. (1994) [Pubmed]
  10. Impaired prostate tumorigenesis in Egr1-deficient mice. Abdulkadir, S.A., Qu, Z., Garabedian, E., Song, S.K., Peters, T.J., Svaren, J., Carbone, J.M., Naughton, C.K., Catalona, W.J., Ackerman, J.J., Gordon, J.I., Humphrey, P.A., Milbrandt, J. Nat. Med. (2001) [Pubmed]
  11. Natural history of progression after PSA elevation following radical prostatectomy. Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D., Walsh, P.C. JAMA (1999) [Pubmed]
  12. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. Langman, M.J., Jensen, D.M., Watson, D.J., Harper, S.E., Zhao, P.L., Quan, H., Bolognese, J.A., Simon, T.J. JAMA (1999) [Pubmed]
  13. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. Verschuren, W.M., Jacobs, D.R., Bloemberg, B.P., Kromhout, D., Menotti, A., Aravanis, C., Blackburn, H., Buzina, R., Dontas, A.S., Fidanza, F. JAMA (1995) [Pubmed]
  14. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. Langer, C.J., Leighton, J.C., Comis, R.L., O'Dwyer, P.J., McAleer, C.A., Bonjo, C.A., Engstrom, P.F., Litwin, S., Ozols, R.F. J. Clin. Oncol. (1995) [Pubmed]
  15. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. Markowitz, G.S., Radhakrishnan, J., Kambham, N., Valeri, A.M., Hines, W.H., D'Agati, V.D. J. Am. Soc. Nephrol. (2000) [Pubmed]
  16. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Blot, S.I., Vandewoude, K.H., Hoste, E.A., Colardyn, F.A. Arch. Intern. Med. (2002) [Pubmed]
  17. Prognosis of chronic duodenal ulcer: a prospective study of the effects of demographic and environmental factors and ulcer healing. Nasiry, R.W., McIntosh, J.H., Byth, K., Piper, D.W. Gut (1987) [Pubmed]
  18. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Burge, M.R., Castillo, K.R., Schade, D.S. Diabetes Care (1997) [Pubmed]
  19. Compensated cirrhosis: natural history and prognostic factors. Ginés, P., Quintero, E., Arroyo, V., Terés, J., Bruguera, M., Rimola, A., Caballería, J., Rodés, J., Rozman, C. Hepatology (1987) [Pubmed]
  20. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Jaeger, C., Brendel, M.D., Hering, B.J., Eckhard, M., Bretzel, R.G. Diabetes (1997) [Pubmed]
  21. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Collett, K., Eide, G.E., Arnes, J., Stefansson, I.M., Eide, J., Braaten, A., Aas, T., Otte, A.P., Akslen, L.A. Clin. Cancer Res. (2006) [Pubmed]
  22. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Widschwendter, A., Tonko-Geymayer, S., Welte, T., Daxenbichler, G., Marth, C., Doppler, W. Clin. Cancer Res. (2002) [Pubmed]
  23. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kovesdy, C.P., Trivedi, B.K., Kalantar-Zadeh, K., Anderson, J.E. Kidney Int. (2006) [Pubmed]
  24. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Caracciolo, E.A., Davis, K.B., Sopko, G., Kaiser, G.C., Corley, S.D., Schaff, H., Taylor, H.A., Chaitman, B.R. Circulation (1995) [Pubmed]
  25. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Davidson, B., Goldberg, I., Gotlieb, W.H., Kopolovic, J., Ben-Baruch, G., Reich, R. Clin. Cancer Res. (2003) [Pubmed]
  26. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. Smyth, P.P., Shering, S.G., Kilbane, M.T., Murray, M.J., McDermott, E.W., Smith, D.F., O'Higgins, N.J. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  27. Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort. Morawetz, R.A., Rizzardi, G.P., Glauser, D., Rutschmann, O., Hirschel, B., Perrin, L., Opravil, M., Flepp, M., von Overbeck, J., Glauser, M.P., Ghezzi, S., Vicenzi, E., Poli, G., Lazzarin, A., Pantaleo, G. Eur. J. Immunol. (1997) [Pubmed]
  28. Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. Results of a multivariate survival analysis. Molica, S., Levato, D., Dell' Olio, M., Cascavilla, N., Matera, R., Minervini, M., Dattilo, A., Carotenuto, M., Musto, P. Haematologica (1997) [Pubmed]
  29. Placebo-controlled trial of prednisolone in children intubated for croup. Tibballs, J., Shann, F.A., Landau, L.I. Lancet (1992) [Pubmed]
  30. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Fawcett, J., Clark, D.C., Aagesen, C.A., Pisani, V.D., Tilkin, J.M., Sellers, D., McGuire, M., Gibbons, R.D. Arch. Gen. Psychiatry (1987) [Pubmed]
  31. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Illei, G.G., Austin, H.A., Crane, M., Collins, L., Gourley, M.F., Yarboro, C.H., Vaughan, E.M., Kuroiwa, T., Danning, C.L., Steinberg, A.D., Klippel, J.H., Balow, J.E., Boumpas, D.T. Ann. Intern. Med. (2001) [Pubmed]
  32. Three-year outcomes for maintenance therapies in recurrent depression. Frank, E., Kupfer, D.J., Perel, J.M., Cornes, C., Jarrett, D.B., Mallinger, A.G., Thase, M.E., McEachran, A.B., Grochocinski, V.J. Arch. Gen. Psychiatry (1990) [Pubmed]
  33. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Marder, S.R., Wirshing, W.C., Van Putten, T., Mintz, J., McKenzie, J., Johnston-Cronk, K., Lebell, M., Liberman, R.P. Arch. Gen. Psychiatry (1994) [Pubmed]
  34. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. Bremnes, R.M., Veve, R., Gabrielson, E., Hirsch, F.R., Baron, A., Bemis, L., Gemmill, R.M., Drabkin, H.A., Franklin, W.A. J. Clin. Oncol. (2002) [Pubmed]
  35. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Lo, H.W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.F., Hung, M.C. Cancer Res. (2005) [Pubmed]
  36. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Koukourakis, M.I., Giatromanolaki, A., Brekken, R.A., Sivridis, E., Gatter, K.C., Harris, A.L., Sage, E.H. Cancer Res. (2003) [Pubmed]
  37. SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro. Orlandi, R., Cattaneo, M., Troglio, F., Casalini, P., Ronchini, C., Ménard, S., Biunno, I. Cancer Res. (2002) [Pubmed]
  38. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Raunio, H., Juvonen, R., Pasanen, M., Pelkonen, O., Pääkkö, P., Soini, Y. Hepatology (1998) [Pubmed]
  39. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Denkert, C., Weichert, W., Pest, S., Koch, I., Licht, D., Köbel, M., Reles, A., Sehouli, J., Dietel, M., Hauptmann, S. Cancer Res. (2004) [Pubmed]
  40. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Ayala, G., Wang, D., Wulf, G., Frolov, A., Li, R., Sowadski, J., Wheeler, T.M., Lu, K.P., Bao, L. Cancer Res. (2003) [Pubmed]
  41. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Kondo, S., Hirano, S., Ambo, Y., Tanaka, E., Okushiba, S., Morikawa, T., Katoh, H. Ann. Surg. (2004) [Pubmed]
  42. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Heimberger, A.B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., Aldape, K. Clin. Cancer Res. (2005) [Pubmed]
  43. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Schols, A.M., Slangen, J., Volovics, L., Wouters, E.F. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
WikiGenes - Universities